FUT6

Summary

FUT6 (fucosyltransferase 6, HGNC:4017) is a protein-coding gene on chromosome 19p13.3, encoding 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6 (P51993). Catalyzes the transfer of L-fucose, from a guanosine diphosphate-beta-L-fucose, to the N-acetyl glucosamine (GlcNAc) of a distal alpha2,3 sialylated lactosamine unit of a glycoprotein- or a glycolipid-linked sialopolylactosamines chain or of a distal or internal lactosamine unit….

The protein encoded by this gene is a Golgi stack membrane protein that is involved in the creation of sialyl-Lewis X, an E-selectin ligand. Mutations in this gene are a cause of fucosyltransferase-6 deficiency. Two transcript variants encoding the same protein have been found for this gene.

Source: NCBI Gene 2528 — RefSeq curated summary.

At a glance

• Gene–disease (curated): fucosyltransferase 6 deficiency (No Known Disease Relationship, GenCC)
• GWAS associations: 46 (top 2% of genes corpus-wide)
• Clinical variants (ClinVar): 102 total
• GTEx eGene: eQTL in 4 tissues, sQTL in 4 (q < 0.05)
• Constraint (gnomAD): pLI 0.10 (LoF-tolerant), LOEUF 1.84 (unconstrained)
• MANE Select transcript: NM_000150
• Notable: 102 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4017
Approved symbol	FUT6
Name	fucosyltransferase 6
Location	19p13.3
Locus type	gene with protein product
Status	Approved
Aliases	FT1A, FCT3A, FucT-VI, FLJ40754
Ensembl gene	ENSG00000156413
Ensembl biotype	protein_coding
OMIM	136836
Entrez	2528

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 14 protein_coding, 2 retained_intron

MANE Select: ENST00000318336

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 3, TSL 2: 1, TSL 4: 2, TSL 5: 4

ENST00000318336, ENST00000286955, ENST00000524754, ENST00000526499, ENST00000527106, ENST00000528505, ENST00000531085, ENST00000531199, ENST00000532464, ENST00000591079, ENST00000592563, ENST00000850998, ENST00000905019, ENST00000905020, ENST00000905021, ENST00000962499

RefSeq mRNA: 10 — MANE Select: NM_000150 NM_000150, NM_001040701, NM_001369502, NM_001369504, NM_001369505, NM_001381955, NM_001381956, NM_001381957, NM_001381958, NM_001381959

CCDS: CCDS12152

Canonical transcript exons

ENST00000318336 — 3 exons

Exon	Start	End
ENSE00001518735	5834950	5835077
ENSE00002168889	5838677	5839702
ENSE00002186798	5830408	5832579

Expression profiles

Bgee: expression breadth ubiquitous, 205 present calls, max score 97.27.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.9642 / max 126.9678, expressed in 73 samples.

Highest expression (Bgee): lower esophagus mucosa, pharyngeal mucosa, olfactory bulb, buccal mucosa cell, tongue squamous epithelium.

Genetic regulation across tissues (GTEx eQTL / sQTL)

FUT6 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 4 tissues and its splicing (sQTL) in 4 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

8 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Esophagus Mucosa	sqtl	2.0e-34	-0.94	19:5832888:C:A
Minor Salivary Gland	sqtl	6.5e-10	-0.88	19:5832888:C:A
Esophagus Mucosa	eqtl	8.3e-09	+0.14	19:5833611:T:C
Testis	eqtl	2.2e-07	+0.47	19:5859399:T:C
Colon Transverse	sqtl	3.3e-05	-0.39	19:5832888:C:A
Pancreas	eqtl	6.1e-03	+0.24	19:5819915:A:G
Kidney Cortex	sqtl	1.8e-02	-0.89	19:5837500:C:T
Lung	eqtl	4.9e-02	+0.31	19:5512800:C:T

FANTOM5 promoters

5 alternative TSS:

Promoter ID	TPM avg	Samples expressed
178565	0.6058	70
178564	0.2572	44
178566	0.0527	14
178567	0.0435	11
178568	0.0050	4

Top tissues by expression

showing 100 of 238 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	97.27	gold quality
pharyngeal mucosa	UBERON:0000355	97.21	gold quality
olfactory bulb	UBERON:0002264	96.33	silver quality
buccal mucosa cell	CL:0002336	96.04	gold quality
tongue squamous epithelium	UBERON:0006919	95.94	gold quality
pancreatic ductal cell	CL:0002079	95.77	gold quality
nasal cavity epithelium	UBERON:0005384	95.66	gold quality
type B pancreatic cell	CL:0000169	95.52	silver quality
ileal mucosa	UBERON:0000331	95.37	gold quality
esophagus squamous epithelium	UBERON:0006920	95.22	gold quality
epithelium of esophagus	UBERON:0001976	94.86	gold quality
amniotic fluid	UBERON:0000173	94.54	gold quality
trachea	UBERON:0003126	93.77	gold quality
esophagus mucosa	UBERON:0002469	93.73	gold quality
oral cavity	UBERON:0000167	93.53	gold quality
squamous epithelium	UBERON:0006914	93.48	gold quality
cervix squamous epithelium	UBERON:0006922	93.03	silver quality
mucosa of transverse colon	UBERON:0004991	92.91	gold quality
adult mammalian kidney	UBERON:0000082	91.23	gold quality
nephron tubule	UBERON:0001231	90.92	gold quality
body of tongue	UBERON:0011876	90.77	gold quality
cervix epithelium	UBERON:0004801	90.74	gold quality
tongue	UBERON:0001723	90.51	gold quality
superior surface of tongue	UBERON:0007371	90.11	gold quality
jejunal mucosa	UBERON:0000399	90.05	gold quality
saliva-secreting gland	UBERON:0001044	89.65	gold quality
mouth mucosa	UBERON:0003729	89.51	gold quality
parotid gland	UBERON:0001831	89.35	gold quality
minor salivary gland	UBERON:0001830	89.19	gold quality
gingiva	UBERON:0001828	89.01	gold quality
gingival epithelium	UBERON:0001949	88.98	silver quality
duodenum	UBERON:0002114	88.92	gold quality
triceps brachii	UBERON:0001509	88.48	silver quality
colonic mucosa	UBERON:0000317	88.22	gold quality
renal medulla	UBERON:0000362	88.15	gold quality
kidney epithelium	UBERON:0004819	88.09	gold quality
gluteal muscle	UBERON:0002000	87.24	silver quality
mucosa of sigmoid colon	UBERON:0004993	87.21	gold quality
epithelium of nasopharynx	UBERON:0001951	87.12	gold quality
kidney	UBERON:0002113	86.91	gold quality
epithelial cell of pancreas	CL:0000083	86.00	silver quality
tibialis anterior	UBERON:0001385	85.82	silver quality
vastus lateralis	UBERON:0001379	85.56	silver quality
jejunum	UBERON:0002115	84.68	gold quality
adult organism	UBERON:0007023	84.50	gold quality
mucosa of paranasal sinus	UBERON:0005030	84.40	gold quality
palpebral conjunctiva	UBERON:0001812	84.33	gold quality
bronchus	UBERON:0002185	84.12	gold quality
nasal cavity mucosa	UBERON:0001826	83.95	gold quality
epithelium of bronchus	UBERON:0002031	83.84	gold quality
renal glomerulus	UBERON:0000074	83.46	gold quality
diaphragm	UBERON:0001103	83.28	gold quality
metanephric glomerulus	UBERON:0004736	83.28	gold quality
tonsil	UBERON:0002372	83.12	gold quality
left ventricle myocardium	UBERON:0006566	82.97	silver quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	82.88	silver quality
superficial temporal artery	UBERON:0001614	82.59	silver quality
rectum	UBERON:0001052	82.56	gold quality
vena cava	UBERON:0004087	82.19	gold quality
myocardium	UBERON:0002349	81.54	silver quality
lower lobe of lung	UBERON:0008949	81.43	silver quality
olfactory segment of nasal mucosa	UBERON:0005386	81.21	gold quality
bronchial epithelial cell	CL:0002328	80.87	gold quality
small intestine	UBERON:0002108	80.26	gold quality
gall bladder	UBERON:0002110	80.24	gold quality
hair follicle	UBERON:0002073	80.04	silver quality
right lobe of liver	UBERON:0001114	80.01	gold quality
small intestine Peyer’s patch	UBERON:0003454	79.85	gold quality
lateral globus pallidus	UBERON:0002476	79.44	silver quality
cortex of kidney	UBERON:0001225	79.41	gold quality
metanephros	UBERON:0000081	79.37	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	79.30	silver quality
substantia nigra pars reticulata	UBERON:0001966	79.25	silver quality
mucosa of urinary bladder	UBERON:0001259	79.11	silver quality
male germ cell	CL:0000015	78.83	silver quality
CA1 field of hippocampus	UBERON:0003881	78.75	silver quality
lateral nuclear group of thalamus	UBERON:0002736	78.74	gold quality
seminal vesicle	UBERON:0000998	78.48	gold quality
transverse colon	UBERON:0001157	78.45	gold quality
liver	UBERON:0002107	78.24	gold quality
substantia nigra pars compacta	UBERON:0001965	77.67	silver quality
periodontal ligament	UBERON:0008266	77.15	gold quality
cardiac muscle of right atrium	UBERON:0003379	77.04	silver quality
sperm	CL:0000019	77.02	silver quality
orbitofrontal cortex	UBERON:0004167	76.90	silver quality
vagina	UBERON:0000996	76.67	gold quality
secondary oocyte	CL:0000655	76.60	silver quality
dorsal plus ventral thalamus	UBERON:0001897	76.59	silver quality
thymus	UBERON:0002370	76.44	silver quality
oviduct epithelium	UBERON:0004804	76.30	gold quality
cranial nerve II	UBERON:0000941	75.95	silver quality
inferior olivary complex	UBERON:0002127	75.70	silver quality
ventral tegmental area	UBERON:0002691	75.53	silver quality
mammary duct	UBERON:0001765	75.05	silver quality
epithelium of mammary gland	UBERON:0003244	74.96	silver quality
upper leg skin	UBERON:0004262	74.87	silver quality
inferior vagus X ganglion	UBERON:0005363	74.49	silver quality
caecum	UBERON:0001153	74.39	gold quality
pylorus	UBERON:0001166	74.37	gold quality
germinal epithelium of ovary	UBERON:0001304	74.27	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	57.06
E-ANND-3	yes	6.62

HPA expression

RNA tissue specificity: Tissue enhanced

57 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Esophagus	tissue	39.3	not detected
Salivary gland	tissue	30.8	not detected
Kidney	tissue	30.3	low
Duodenum	tissue	26.9	high
Vagina	tissue	25.6	not detected
Small intestine	tissue	25.4	medium
Colon	tissue	16.3	medium
Rectum	tissue	10.9	medium
Gallbladder	tissue	8.7	medium
Cervix	tissue	6.6	low
Tonsil	tissue	6.2	low
Stomach 1	tissue	4.6	medium
Pancreas	tissue	3.5	low
Liver	tissue	3.5	not detected
Appendix	tissue	2.5	medium
Seminal vesicle	tissue	2.3	low
Retina	tissue	1.9
Breast	tissue	1.6	low
Choroid plexus	tissue	1.1
Cerebral cortex	tissue	0.7	low
Cerebellum	tissue	0.7	low
Pons	tissue	0.6
Basal ganglia	tissue	0.6	low
Putamen	tissue	0.6
Amygdala	tissue	0.6
Medulla oblongata	tissue	0.6
Hippocampal formation	tissue	0.6
Retrosplenial cortex	tissue	0.6
Nucleus accumbens	tissue	0.5
Midbrain	tissue	0.5
Thalamus	tissue	0.5
Hypothalamus	tissue	0.5
Substantia nigra	tissue	0.5
Locus coeruleus	tissue	0.5
Spinal cord	tissue	0.5
Hippocampus	tissue	0.5	not detected
Postcentral gyrus	tissue	0.5
Occipital cortex	tissue	0.5
Smooth muscle	tissue	0.4	low
Endometrium 1	tissue	0.3	low
Bone marrow	tissue	0.3	not detected
Fallopian tube	tissue	0.2	low
Lymph node	tissue	0.1	not detected
Testis	tissue	0.1	medium
Adipose tissue	tissue	0.1	not detected
Heart muscle	tissue	0.0	low
Parathyroid gland	tissue	0.0	low
Skeletal muscle	tissue	0.0	low
Urinary bladder	tissue	0.0	medium
Epididymis	tissue	0.0	low
Placenta	tissue	0.0	low
Thyroid gland	tissue	0.0	low
Lung	tissue	0.0	low
Spleen	tissue	0.0	low
Bronchus	tissue	-1.0	low
Soft tissue 1	tissue	-1.0	low
Oral mucosa	tissue	-1.0	low

Brain sub-regions (HPA Brain Atlas): detected in 185; highest nTPM — Angular gyrus (white matter) (0.7), Area striata (white matter) (0.7), Flocculonodular lobe (0.7), Parieto-temporal junction (white matter) (0.7), Piriform cortex (0.7).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting FUT6 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 33 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-4316	99.37	65.75	1360
HSA-MIR-499A-3P	99.18	69.20	1392
HSA-MIR-499B-3P	99.18	69.27	1391
HSA-MIR-6504-3P	99.17	69.31	2891
HSA-MIR-7151-3P	99.04	69.72	2370
HSA-MIR-6506-5P	99.04	65.66	1386
HSA-MIR-3619-5P	99.00	68.87	2308
HSA-MIR-4742-5P	98.89	68.41	1542
HSA-MIR-2355-5P	98.83	65.51	1589
HSA-MIR-6840-3P	98.68	65.95	1923
HSA-MIR-7977	98.65	66.18	2590
HSA-MIR-4710	98.61	65.96	1048
HSA-MIR-619-5P	98.57	64.97	1988
HSA-MIR-4290	98.51	65.17	907
HSA-MIR-4726-3P	98.49	63.89	1385
HSA-MIR-5089-5P	98.45	66.06	1388
HSA-MIR-6764-3P	98.44	67.64	1153
HSA-MIR-6824-3P	98.44	67.62	1154
HSA-MIR-5008-5P	98.42	65.87	1019
HSA-MIR-6516-5P	98.42	70.19	1551
HSA-MIR-6831-5P	98.26	67.20	990
HSA-MIR-3665	97.73	65.08	975
HSA-MIR-2467-5P	97.36	67.71	991
HSA-MIR-125A-3P	97.04	66.92	902
HSA-MIR-874-5P	96.93	63.92	1014

Functional genomics

gnomAD constraint: pLI 0.098, LOEUF 1.84, missense Z 0.886 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000318336 — one region, missense o/e 0.92.

Literature-anchored findings (GeneRIF, showing 23)

• endo-beta-galactosidase-sensitive and mAb FH6-reactive carbohydrate chains are generated under the control of expression levels of FUT6 and involved in the adhesion of colon carcinoma cells to liver sections. (PMID:12670495)
• 5’UT-exons A or C have higher expression of FUT8 transcripts and higher alpha6-fucosyltransferase activity (PMID:14514715)
• IL-1 beta-induced sLeX expression on HuH-7 cells was suppressed by transfection of gene-specific small interference RNAs against FUT VI and ST3Gal IV but not against FUT IV and ST3Gal III. (PMID:17054948)
• two defined regions in the 5’-flanking region of the FUT VI transcription start site are critical for FUT VI transcription in HepG2 cells (PMID:18274891)
• results suggested that PKR is the primary target for HSV-1 early RNA during induction of FUT3, FUT5, and FUT6 (PMID:19349624)
• GALNT14 and FUT3/6 H-scores were significantly higher in non-small cell lung cancer cell lines sensitive to dulanermin and drozitumab versus resistant cell lines (PMID:20179215)
• The biosynthesis of the selectin-ligand sialyl Lewis x in colorectal cancer tissues is regulated by fucosyltransferase VI and can be inhibited by an RNA interference-based approach. (PMID:20965272)
• these results suggest that FUT6 plays an important role in hepatocellular carcinoma growth by regulating the PI3K/Akt signaling pathway. (PMID:22155250)
• Results suggest that FUT4-, FUT6- or FUT8-mediated MDR in human HCC is associated with the activation of the PI3K/Akt pathway and the expression of MRP1. (PMID:24232099)
• In normal colon samples a significant relationship between sLe(x) expression and the ratio between FUT6/B4GALNT2 activities exists, demonstrating for the first time a role for B4GALNT2 in sLe(x) inhibition in vivo (PMID:24953560)
• The T allele of rs3760776 might repress the transcription of the FUT6 gene. (PMID:25962326)
• There were significant differences between the type 2 diabetes mellitus patients and controls in the risk allele distributions of rs3792267 (CAPN10) (P = 0.002), rs1501299 (APM1) (P = 0.017), and rs3760776 (FUT6) (P = 0.031). (PMID:27374856)
• ur results strongly showed that the low expression of FUT6 regulated by miR-106b contributed to cell migration, invasion, and proliferation in human breast cancer. (PMID:27519168)
• meta-analysis identified new variants, rs3760775 (P = 1.2 x 10-23) and rs78060698 (P = 8.3 x 10-17) in FUT6 to be associated with circulating B12 concentrations. (PMID:28334792)
• data suggest that both FUT5 and FUT6 can promote the development of colorectal cancer (CRC) via the PI3K/Akt signalling pathway, which is regulated by miR-125a-3p. miR-125a-3p may serve as a predictive biomarker and a potential therapeutic target in CRC treatment. (PMID:28771224)
• we identified a novel association of a common loss-of-function, missense variant in Fucosyltransferase 6 (FUT6; rs17855739,p.Glu274Lys, P = 9.02 x 10-24) with higher soluble E-selectin levels. This variant is considerably more common in populations of African ancestry compared to non-African ancestry populations. (PMID:30307499)
• findings indicated that HOTAIR/miR-326/FUT6 axis mediated colorectal cancer (CRC) procession through alpha1, 3-fucosylated CD44 via PI3K/AKT/mTOR pathway. This work rendered new therapeutic targets for CRC. (PMID:30742932)
• Overexpressed N-fucosylation on cell surface promotes the migration and invasion of metastatic pancreatic cancer cells. Overexpressed N-fucosylation is driven by gene FUT3, 5, and 6 in metastatic pancreatic cancer cells. (PMID:30808544)
• Using Eukaryotic Expression Systems to Generate Human alpha1,3-Fucosyltransferases That Effectively Create Selectin-Binding Glycans on Stem Cells. (PMID:32901486)
• FUT6 deficiency compromises basophil function by selectively abrogating their sialyl-Lewis x expression. (PMID:34215830)
• FUT6 inhibits the proliferation, migration, invasion, and EGF-induced EMT of head and neck squamous cell carcinoma (HNSCC) by regulating EGFR/ERK/STAT signaling pathway. (PMID:36151332)
• Correlation of FUT3 and FUT6 Gene Polymorphisms With Helicobacter pylori Infection. (PMID:39108208)
• FUT6 Suppresses the Proliferation, Migration, Invasion, and Epithelial-Mesenchymal Transition of Esophageal Carcinoma Cells via the Epidermal Growth Factor Receptor/Extracellular Signal-Regulated Kinase Signaling Pathway. (PMID:39375968)

Cross-species orthologs

22 orthologs

Organism	Symbol	Gene ID
danio_rerio	fut9b.3	ENSDARG00000027699
danio_rerio	fut9d	ENSDARG00000028098
danio_rerio	fut7	ENSDARG00000044775
danio_rerio	fut9b.2	ENSDARG00000058299
danio_rerio	fut9b.1	ENSDARG00000067524
danio_rerio	fut9b.4	ENSDARG00000086603
danio_rerio		ENSDARG00000100247
danio_rerio	fut9b.5	ENSDARG00000102426
danio_rerio	fut9b.6	ENSDARG00000102554
drosophila_melanogaster	FucTD	FBGN0035217
caenorhabditis_elegans		WBGENE00001505
caenorhabditis_elegans		WBGENE00001507
caenorhabditis_elegans		WBGENE00004010
caenorhabditis_elegans		WBGENE00006402
caenorhabditis_elegans		WBGENE00007211
caenorhabditis_elegans		WBGENE00012922
caenorhabditis_elegans		WBGENE00016163
caenorhabditis_elegans		WBGENE00017343
caenorhabditis_elegans		WBGENE00043986
caenorhabditis_elegans		WBGENE00044383
caenorhabditis_elegans		WBGENE00194870
caenorhabditis_elegans		WBGENE00206359

Paralogs (7): FUT5 (ENSG00000130383), FUT3 (ENSG00000171124), FUT9 (ENSG00000172461), POFUT3 (ENSG00000172728), FUT7 (ENSG00000180549), FUT4 (ENSG00000196371), POFUT4 (ENSG00000196968)

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Pan troglodytes	Q659L0	100.0%	Diamond
Mus musculus	O88819	99.4%	Diamond
Canis lupus familiaris	Q659L1	99.4%	Diamond
Rattus norvegicus	Q99JB3	99.2%	Diamond
Cricetulus griseus	Q9JIG1	98.9%	Diamond
Bos taurus	Q8HZR2	97.8%	Diamond
Gorilla gorilla gorilla	Q8HYJ6	96.9%	Diamond
Hylobates lar	Q8HYJ3	96.5%	Diamond
Pongo pygmaeus	Q8HYJ4	96.3%	Diamond
Oryzias latipes	Q5F2N2	84.7%	Diamond
Takifugu rubripes	Q70AG8	84.7%	Diamond
Xenopus tropicalis	Q6A1G3	84.4%	Diamond
Xenopus laevis	Q6NTZ6	84.3%	Diamond
Arabidopsis thaliana	Q9FX97	77.4%	Diamond
Gallus gallus	Q8AWC7	74.2%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
NDUFA11	protein-coding	126328
FUT3	protein-coding	2525
FUT5	protein-coding	2527
NRTN	protein-coding	4902
PRR22	protein-coding	163154
DUS3L	protein-coding	56931
CATSPERD	protein-coding	257062
VMAC	protein-coding	400673

Protein

Protein identifiers

4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6 — P51993 (reviewed: P51993)

Alternative names: Fucosyltransferase 6, Fucosyltransferase VI, Galactoside 3-L-fucosyltransferase

All UniProt accessions (5): E9PJ18, E9PJB4, E9PP56, E9PS22, P51993

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the transfer of L-fucose, from a guanosine diphosphate-beta-L-fucose, to the N-acetyl glucosamine (GlcNAc) of a distal alpha2,3 sialylated lactosamine unit of a glycoprotein- or a glycolipid-linked sialopolylactosamines chain or of a distal or internal lactosamine unit of a neutral glycoprotein- or a glycolipid-linked polylactosamines chain through an alpha-1,3 glycosidic linkage and participates in surface expression of the sialyl Lewis X (sLe(x)), Lewis X (Le(x)) and non sialylated VIM2 determinants. Moreover transfers fucose to H-type 2 (Fucalpha1-2Galbeta1-4GlcNAc) chain acceptor substrates and participates in difucosylated sialyl Lewis x determinants. Also fucosylates a polylactosamine substrate having a 6 sulfate modification at the GlcNAc moiety and gives rise to sialyl and non-sialyl 6-sulfo lewis X. Does not have activity towards type 1 ((Galbeta1-3GlcNAc)) and H-type 1 chain (Fucalpha1-2Galbeta1-3GlcNAc) acceptors substrates. Does not have alpha(1,3)-fucosyltransferase activity.

Subunit / interactions. Homodimer and monomer. Monomer (secreted form).

Subcellular location. Golgi apparatus. Golgi stack membrane. Secreted.

Tissue specificity. Kidney, liver, colon, small intestine, bladder, uterus and salivary gland.

Post-translational modifications. N-glycosylated. Proteolytic cleavage releases a secreted glycoform of 43 kDa.

Pathway. Protein modification; protein glycosylation.

Polymorphism. Expression of alpha(1,3)-fucosyltransferase in plasma can vary among different populations. 9% of individuals on the isle of Java (Indonesia) do not express this enzyme. Ninety-five percent of plasma alpha(1,3)-fucosyltransferase-deficient individuals have Lewis negative phenotype on red cells, suggesting strong linkage disequilibrium between these two traits. Variations in FUT6 are responsible for plasma alpha(1,3)-fucosyltransferase deficiency [MIM:613852].

Similarity. Belongs to the glycosyltransferase 10 family.

Isoforms (2)

UniProt ID	Names	Canonical?
P51993-1	1	yes
P51993-2	2

RefSeq proteins (10): NP_000141, NP_001035791, NP_001356431, NP_001356433, NP_001356434, NP_001368884, NP_001368885, NP_001368886, NP_001368887, NP_001368888 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001503	Glyco_trans_10	Family
IPR031481	Glyco_tran_10_N	Domain
IPR038577	GT10-like_C_sf	Homologous_superfamily
IPR055270	Glyco_tran_10_C	Domain

Pfam: PF00852, PF17039

Enzyme classification (BRENDA)

• EC 2.4.1.152 — 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase (BRENDA: 24 organisms, 171 substrates, 55 inhibitors, 103 Km, 24 kcat entries)
• EC 2.4.1.65 — 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase (BRENDA: 16 organisms, 191 substrates, 64 inhibitors, 119 Km, 15 kcat entries)

Substrate kinetics (BRENDA)

105 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
GDP-FUCOSE	0.03–0.244	19
GDP-BETA-L-FUCOSE	0.0001–1.12	18
N-ACETYLLACTOSAMINE	0.0026–0.61	9
GDP-L-FUCOSE	0.005–0.035	8
D-LACTOSE	72–543	6
GAL-BETA-1,4-GLCNAC-O-(CH2)8CO2CH3	0.17–2.2	6
GDP-FUCOSE	0.0016–0.06	5
GDP-L-FUCOSE	0.0055–0.062	5
FUCALPHA(1,2)GALBETA(1,3)GLCNAC	0.1–3.8	5
FUCALPHA(1,2)GALBETA(1,4)GLCNAC	0.7–3.9	4
GALBETA1,4GLCNAC-O(CH2)8CO2CH3	0.37–1.7	4
FUC-ALPHA-1,2GAL-BETA-1,3GLCNAC-SP-BIOTIN	0.2–2.5	4
GAL-BETA-1,3-GLCNAC-O-(CH2)8CO2CH3	8.4–22.7	4
GAL-BETA-1,3GLCNACO(CH2)3NHCO(CH2)5NH-BIOTIN	0.7–3.3	4
GALBETA(1,4)GLCNAC	1.4–23	3

Catalyzed reactions (Rhea)

• a beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl derivative + GDP-beta-L-fucose = a beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl derivative + GDP + H(+) (RHEA:14257)
• a neolactoside VI(3)-alpha-NeuNAc-nLc6Cer + GDP-beta-L-fucose = a neolactoside VI(3)-alpha-NeuAc,V(3)-alphaFuc-nLc6Cer + GDP + H(+) (RHEA:48356)
• a neolactoside nLc6Cer + GDP-beta-L-fucose = beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1’)-ceramide + GDP + H(+) (RHEA:48364)
• a neolactoside nLc6Cer + GDP-beta-L-fucose = beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1’)-Cer + GDP + H(+) (RHEA:48368)
• an alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc derivative + GDP-beta-L-fucose = an alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc derivative + GDP + H(+) (RHEA:52864)
• an N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl derivative + GDP-beta-L-fucose = an alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc derivative + GDP + H(+) (RHEA:56076)
• beta-D-galactosyl-(1->4)-N-acetyl-D-glucosamine + GDP-beta-L-fucose = beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-D-glucosamine + GDP + H(+) (RHEA:62824)
• N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine + GDP-beta-L-fucose = N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosamine + GDP + H(+) (RHEA:62836)
• lactose + GDP-beta-L-fucose = beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-D-glucose + GDP + H(+) (RHEA:62888)
• alpha-L-Fuc-(1->2)-beta-D-Gal-(1->4)-D-Glc + GDP-beta-L-fucose = alpha-L-Fuc-(1->2)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-D-Glc + GDP + H(+) (RHEA:64016)
• a beta-D-galactosyl-(1->4)-N-acetyl-beta-D-6-sulfooxy-glucosaminyl derivative + GDP-beta-L-fucose = a beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-6-sulfooxy-glucosaminyl derivative + GDP + H(+) (RHEA:64032)

UniProt features (19 total): sequence variant 5, mutagenesis site 4, glycosylation site 4, topological domain 2, chain 1, transmembrane region 1, region of interest 1, splice variant 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P51993-F1	89.81	0.79

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Transferases, Metabolic proteins, Predicted membrane proteins, Predicted secreted proteins, Predicted intracellular proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): golgi apparatus

Antibody reliability (HPA): IH approved · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (4)

Type	Positions
N-linked (glcnac…) asparagine	46, 91, 153, 184

Mutagenesis-validated functional residues (4)

Position	Phenotype
73	loss of site-specific fucosylation leading to generation of approximately equal amounts of vim2 and sialyl-lewis x. reverse the …
110	reduces dramatically alpha(1,3)fucosyltransferase activity towards type 2 chain acceptors. loss of site-specific fucosylation leading to …
111	reverse the site-specific fucosylation pattern leading to generation of vim2 predominantly instead of sialyl-lewis x; when associated with …
112	reverse the site-specific fucosylation pattern leading to generation of vim2 predominantly instead of sialyl-lewis x; when associated with …

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 4; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

4 pathways:

ID	Pathway	Evidence
R-HSA-9037629	Lewis blood group biosynthesis	curated
R-HSA-9033658	Blood group systems biosynthesis	—
R-HSA-1430728	Metabolism	—
R-HSA-71387	Metabolism of carbohydrates and carbohydrate derivatives	—

MSigDB gene sets: 126 (showing top): GOBP_OLIGOSACCHARIDE_METABOLIC_PROCESS, MORF_FLT1, MORF_MSH3, GOBP_GLYCOLIPID_BIOSYNTHETIC_PROCESS, GOBP_PROTEIN_N_LINKED_GLYCOSYLATION, GOBP_MONOSACCHARIDE_CATABOLIC_PROCESS, MORF_ESR1, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_SPHINGOLIPID_METABOLIC_PROCESS, GOBP_AMIDE_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, ODONNELL_TARGETS_OF_MYC_AND_TFRC_UP, WAGNER_APO2_SENSITIVITY, GOBP_GLYCOSPHINGOLIPID_BIOSYNTHETIC_PROCESS, GOBP_CARBOHYDRATE_METABOLIC_PROCESS

GO Biological Process (10): protein N-linked glycosylation (GO:0006487), protein O-linked glycosylation (GO:0006493), ceramide metabolic process (GO:0006672), glycosphingolipid biosynthetic process (GO:0006688), glycoprotein biosynthetic process (GO:0009101), oligosaccharide biosynthetic process (GO:0009312), protein O-linked glycosylation via fucose (GO:0036066), L-fucose catabolic process (GO:0042355), lipid metabolic process (GO:0006629), sphingolipid metabolic process (GO:0006665)

GO Molecular Function (5): fucosyltransferase activity (GO:0008417), 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity (GO:0017083), alpha-(1->3)-fucosyltransferase activity (GO:0046920), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757)

GO Cellular Component (6): Golgi membrane (GO:0000139), extracellular region (GO:0005576), Golgi apparatus (GO:0005794), Golgi cisterna membrane (GO:0032580), extracellular exosome (GO:0070062), membrane (GO:0016020)

Reactome top-level categories

3 top-level categories:

Category	Pathways
Blood group systems biosynthesis	1
Metabolism	1
Metabolism of carbohydrates and carbohydrate derivatives	1

GO top-level categories

29 GO namespaces:

Category	Terms
glycoprotein biosynthetic process	2
cellular anatomical structure	2
sphingolipid metabolic process	1
glycosphingolipid metabolic process	1
glycolipid biosynthetic process	1
sphingolipid biosynthetic process	1
macromolecule biosynthetic process	1
glycoprotein metabolic process	1
carbohydrate derivative biosynthetic process	1
oligosaccharide metabolic process	1
carbohydrate biosynthetic process	1
protein O-linked glycosylation	1
hexose catabolic process	1
L-fucose metabolic process	1
primary metabolic process	1
lipid metabolic process	1
hexosyltransferase activity	1
alpha-(1->3)-fucosyltransferase activity	1
fucosyltransferase activity	1
catalytic activity	1
transferase activity	1
Golgi apparatus	1
bounding membrane of organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle membrane	1
Golgi cisterna	1
extracellular vesicle	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 10 of 22 annotations. The rest are phylogenetic / computational / electronic (IEA).

10 experimentally-supported GO terms:

GO term	NS	Evidence
ceramide metabolic process	BP	direct assay
glycosphingolipid biosynthetic process	BP	direct assay
protein N-linked glycosylation	BP	direct assay
protein O-linked glycosylation	BP	direct assay
protein O-linked glycosylation via fucose	BP	direct assay
Golgi apparatus	CC	direct assay
extracellular exosome	CC	high-throughput assay
extracellular region	CC	direct assay
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity	MF	direct assay
fucosyltransferase activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 520 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FUT6	FUT1	P19526	896
FUT6	FUT2	Q10981	870
FUT6	B4GALT1	P15291	847
FUT6	FUT8	Q9BYC5	761
FUT6	SELE	P16111	678
FUT6	B4GALNT2	Q8NHY0	613
FUT6	SELP	P16109	610
FUT6	ST3GAL3	Q11203	576
FUT6	ORM2	P19652	558
FUT6	ORM1	P02763	553
FUT6	ST3GAL4	Q11206	548
FUT6	ST6GAL1	P15907	535
FUT6	MGAT5	Q09328	533
FUT6	POFUT1	Q9H488	513
FUT6	ST3GAL1	Q11201	494

Disease & clinical

Genetic variants

Variant evidence for FUT6: 102 ClinVar records (0 pathogenic / likely pathogenic); 46 GWAS associations.

ClinVar

102 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	85
Likely benign	13
Benign	2

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 19 predictions of 473):

Position(s)	Effect	Δscore	Sites
19:5832587	acceptor_gain	0.9900
19:5832580–5832581	acceptor_loss	0.9700	6
19:5838185	donor_gain	0.9500
19:5839172	donor_gain	0.9100
19:5838186	donor_gain	0.9000
19:5838675–5838676	donor_loss	0.8700	5
19:5832469	acceptor_gain	0.8600
19:5839311	donor_gain	0.8500
19:5839525	donor_gain	0.8500
19:5838675	donor_loss	0.8300

AlphaMissense

692 missense substitutions predicted likely pathogenic (of 2,345 scored), across 167 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
F242	8	0.941	0.996
N248	8	0.935	0.982
F289	8	0.918	0.993
F246	8	0.902	0.940
F152	8	0.868	0.978
F319	8	0.866	0.945
H291	8	0.834	0.945
D253	8	0.833	0.910
H108	8	0.820	0.922
F295	7	0.954	0.988
K258	7	0.950	0.977
W260	7	0.949	0.984
E247	7	0.948	0.992
W321	7	0.947	0.986
C337	7	0.945	0.974
C90	7	0.940	0.981
F358	7	0.935	0.985
C340	7	0.928	0.960
F71	7	0.918	0.982
E137	7	0.917	0.967

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

4 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	3.62e-09
Kidney Renal Papillary Cell Carcinoma (TCGA)	favorable	1.08e-05
Kidney Renal Clear Cell Carcinoma (validation)	favorable	0.000218
Head and Neck Squamous Cell Carcinoma (TCGA)	favorable	0.000321

Disease associations

OMIM: gene MIM:136836 | disease phenotypes:

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
fucosyltransferase 6 deficiency	No Known Disease Relationship	Autosomal recessive

Mondo (1): fucosyltransferase 6 deficiency (MONDO:0013462)

GWAS associations

showing 30 of 46 associations:

Study	Trait	p-value
GCST001808_5	Tumor biomarkers	3e-290
GCST009648_1	Serum cancer antigen 19.9 levels	2e-179
GCST001808_3	Tumor biomarkers	5e-132
GCST001808_4	Tumor biomarkers	2e-56
GCST001808_1	Tumor biomarkers	1e-35
GCST005046_10	N-glycan levels	3e-29
GCST90011899_76	Aspartate aminotransferase levels	8e-24
GCST004161_1	Vitamin B12 levels	1e-23
GCST005046_9	N-glycan levels	1e-21
GCST005046_12	N-glycan levels	3e-20
GCST007209_7	Gallstone disease	7e-20
GCST005046_11	N-glycan levels	5e-19
GCST002485_6	Elevated serum carcinoembryonic antigen levels	8e-19
GCST000925_3	N-glycan levels	4e-17
GCST005046_8	N-glycan levels	9e-17
GCST005046_29	N-glycan levels	1e-16
GCST009650_3	Serum carcinoembryonic antigen levels	5e-16
GCST90013407_149	Liver enzyme levels (gamma-glutamyl transferase)	7e-16
GCST004861_29	Itch intensity from mosquito bite	9e-16
GCST90013406_275	Liver enzyme levels (alkaline phosphatase)	1e-15
GCST003219_45	Advanced age-related macular degeneration	2e-15
GCST004161_4	Vitamin B12 levels	6e-15
GCST011369_36	Iron status biomarkers (ferritin levels)	2e-14
GCST005046_39	N-glycan levels	3e-14
GCST90002380_109	Basophil percentage of white cells	1e-13
GCST004925_7	IgG N-glycosylation phenotypes (multivariate analysis)	2e-13
GCST005046_30	N-glycan levels	2e-13
GCST90002379_91	Basophil count	2e-13
GCST90011900_156	Serum alkaline phosphatase levels	2e-13
GCST001424_6	Vitamin B12 levels	4e-13

EFO canonical traits (from GWAS)

16 canonical traits:

EFO ID	Trait name
EFO:0004999	N-glycan measurement
EFO:0004620	vitamin B12 measurement
EFO:0005127	cancer biomarker measurement
EFO:0005760	serum carcinoembryonic antigen measurement
EFO:1001492	atrophic macular degeneration
EFO:0005090	basophil count
EFO:0007992	basophil percentage of leukocytes
EFO:0007995	basophil percentage of granulocytes
EFO:0008377	mosquito bite reaction itch intensity measurement
EFO:0008378	mosquito bite reaction size measurement
EFO:0005193	serum IgG glycosylation measurement
EFO:0010584	cancer antigen 19.9 measurement
EFO:0004459	ferritin measurement
EFO:0004736	aspartate aminotransferase measurement
EFO:0004533	alkaline phosphatase measurement
EFO:0004532	serum gamma-glutamyl transferase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4443 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

8 measured of 8 human assays (9 total across all organisms); most potent 8 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL6190956	IC50	610 nM
CHEMBL610389	IC50	1390 nM
CHEMBL610391	IC50	1620 nM
CHEMBL610390	IC50	1890 nM
CHEMBL611881	IC50	3340 nM
CHEMBL608046	IC50	3960 nM
Gallic Acid, F	IC50	14000 nM
(-)-Epigallocatechin-3-o-gallate	IC50	58000 nM

ChEMBL bioactivities

11 potent at pChembl≥5 of 12 total, top 11 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.42	Ki	376	nM	CHEMBL610389
6.36	Ki	437	nM	CHEMBL610391
6.29	Ki	511	nM	CHEMBL610390
6.21	IC50	610	nM	CHEMBL6190956
6.04	Ki	901	nM	CHEMBL611881
5.97	Ki	1069	nM	CHEMBL608046
5.86	IC50	1394	nM	CHEMBL610389
5.79	IC50	1618	nM	CHEMBL610391
5.72	IC50	1893	nM	CHEMBL610390
5.48	IC50	3338	nM	CHEMBL611881
5.40	IC50	3957	nM	CHEMBL608046

PubChem BioAssay actives

12 with measured affinity, of 15 total; 7 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[[(2R,3S,4R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [1-[5-(1,2-diphenylethylamino)-5-oxopentyl]triazol-4-yl]methyl hydrogen phosphate	72095: Compound was tested for binding affinity against Fucosyltransferase 6	ki	0.3760	uM
[[(2R,3S,4R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [1-[2-(1,2-diphenylethylamino)-2-oxoethyl]triazol-4-yl]methyl hydrogen phosphate	72095: Compound was tested for binding affinity against Fucosyltransferase 6	ki	0.4370	uM
[[(2R,3S,4R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [1-[5-[(9,10-dioxo-4a,9a-dihydroanthracen-2-yl)amino]-5-oxopentyl]triazol-4-yl]methyl hydrogen phosphate	72095: Compound was tested for binding affinity against Fucosyltransferase 6	ki	0.5110	uM
[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [1-[5-oxo-5-[(4-phenylphenyl)methylamino]pentyl]triazol-4-yl]methyl hydrogen phosphate	2276595: Inhibition of human FUT6	ic50	0.6100	uM
[[(2R,3S,4R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [1-[3-(naphthalen-1-ylmethylamino)-3-oxopropyl]triazol-4-yl]methyl hydrogen phosphate	72095: Compound was tested for binding affinity against Fucosyltransferase 6	ki	0.9010	uM
[[(2R,3S,4R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [1-[4-(1,2-diphenylethylamino)-4-oxobutyl]triazol-4-yl]methyl hydrogen phosphate	72095: Compound was tested for binding affinity against Fucosyltransferase 6	ki	1.0690	uM
[(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate	1799773: SPA Assay from Article 10.1016/j.abb.2004.02.039: “Inhibition of fucosyltransferase VII by gallic acid and its derivatives.”	ic50	1.8000	uM

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Valproic Acid	decreases expression, increases methylation	2
OTX015	decreases expression	1
mivebresib	decreases expression	1
methyleugenol	decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
ochratoxin A	decreases expression	1
ICG 001	increases expression	1
(+)-JQ1 compound	decreases expression	1
Arsenic Trioxide	increases expression	1
Acetaminophen	decreases expression	1
N-Nitrosopyrrolidine	decreases expression	1
Quercetin	decreases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	affects expression	1
Urethane	decreases expression	1
Cyclosporine	decreases expression	1
Sodium Selenite	decreases expression	1
Antirheumatic Agents	increases expression	1
Okadaic Acid	decreases expression	1
Acrylamide	increases expression	1
Particulate Matter	decreases expression	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3598447	Binding	Inhibition of FucT-6 (unknown origin)	Beyond substrate analogues: new inhibitor chemotypes for glycosyltransferases — *Medchemcomm*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for FUT6 across ~30M SureChEMBL compounds — explore on Sugi Predict.